Although most of the studies on PLAC1 expression have been oriented at the transcript level due to the uncertainty of available antibodies, the cumulative data indicate the differential overexpression of this marker in vast majority of solid tumors and cell lines10,20,26–30 making anti-PLAC1 antibodies a potentially suitable vehicle for delivering cytotoxic agents to cancer cells. Here, PLAC1 is linked to cancer.